AstraZeneca is in talks with Bristol Myers Squibb about a potential merger that could create a combined company valued at nearly $400 billion, making it one of the largest pharmaceutical deals in history and the world's fourth-biggest drugmaker by market value.
The discussions have been ongoing over the past few months, but there is no guarantee a deal will be finalized, and talks could still be delayed or fall apart.
A merger would significantly expand AstraZeneca's presence in the U.S. market and could face substantial regulatory scrutiny due to overlapping cancer drug portfolios, with possible antitrust concerns and requirements for divestitures.
Sources:
AstraZeneca and Bristol Myers Squibb mull $400 billion deal
AstraZeneca holds talks with US cancer drug developer in $400bn merger
AstraZeneca and Bristol Myers Squibb mull $400 billion deal
AstraZeneca held talks with Bristol Myers Squibb on $400 ...
AstraZeneca shares drop 7% after report on $400 billion ...
FTSE 100 slips as AstraZeneca drops on Bristol Myers merger talks
Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion mega deal: Report
AstraZeneca Shares Fall on Deal Talks With Bristol-Myers
Reuters on X: "AstraZeneca holds talks with Bristol Myers ...
AstraZeneca, Bristol Myers Squibb Held Tie-Up Talks, FT ...
AstraZeneca and BMS pursue mega-merger to form $400B pharma ...
AstraZeneca and Bristol-Myers Squibb in talks over ...
AstraZeneca in talks over £300bn mega-merger with US ...
AstraZeneca holds talks with Bristol Myers Squibb on mega ...
AstraZeneca Held Talks to Combine With Bristol Myers Squibb ...